PT1075277E - Métodos para detectar e inibir a angiogénese - Google Patents

Métodos para detectar e inibir a angiogénese Download PDF

Info

Publication number
PT1075277E
PT1075277E PT99922828T PT99922828T PT1075277E PT 1075277 E PT1075277 E PT 1075277E PT 99922828 T PT99922828 T PT 99922828T PT 99922828 T PT99922828 T PT 99922828T PT 1075277 E PT1075277 E PT 1075277E
Authority
PT
Portugal
Prior art keywords
tissue
integrin
angiogenesis
agent
methods
Prior art date
Application number
PT99922828T
Other languages
English (en)
Inventor
Judith A Varner
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22187621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1075277(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of PT1075277E publication Critical patent/PT1075277E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99922828T 1998-05-08 1999-05-07 Métodos para detectar e inibir a angiogénese PT1075277E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8485098P 1998-05-08 1998-05-08

Publications (1)

Publication Number Publication Date
PT1075277E true PT1075277E (pt) 2009-05-08

Family

ID=22187621

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99922828T PT1075277E (pt) 1998-05-08 1999-05-07 Métodos para detectar e inibir a angiogénese

Country Status (11)

Country Link
EP (3) EP2327451B1 (pt)
JP (2) JP2002514605A (pt)
AT (1) ATE423570T1 (pt)
AU (1) AU746662B2 (pt)
CA (1) CA2328414C (pt)
CY (1) CY1109062T1 (pt)
DE (1) DE69940465D1 (pt)
DK (1) DK1075277T4 (pt)
ES (1) ES2322723T5 (pt)
PT (1) PT1075277E (pt)
WO (1) WO1999058139A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
GB9909392D0 (en) * 1999-04-24 1999-06-23 Imp Cancer Res Tech Treatment, imaging and diagnosis of disease
US7101975B1 (en) 1999-07-13 2006-09-05 University Of Southern California Method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and β1 integrins
CN1379685A (zh) * 1999-07-13 2002-11-13 南加利福尼亚大学 用基于MMP－9和β1整联蛋白的拮抗剂抑制血管发生的新方法和组合物
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1539247A4 (en) * 2002-07-16 2007-08-29 Univ New Jersey Med ALPHA 5 BETA 1 AND ITS ABILITY TO REGULATE THE CELL SURVIVAL PATH
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP4741242B2 (ja) * 2002-11-26 2011-08-03 アボット バイオセラピューティクス コーポレイション 新脈管形成を調節するα５β１インテグリンへのキメラ及びヒト化抗体
KR20070009637A (ko) 2004-03-24 2007-01-18 피디엘 바이오파르마 인코포레이티드 암 세포 증식을 억제하는 항α5β1 항체의 용도
ATE494913T1 (de) * 2004-11-22 2011-01-15 Ge Healthcare As Kontrastmittel für eine extrazelluläre matrix
DE102005023784A1 (de) * 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
NZ571068A (en) 2006-03-21 2012-06-29 Genentech Inc An antibody that can bind human alpha5beta1
CL2008002856A1 (es) 2007-09-26 2009-01-16 Genentech Inc Anticuerpo novedoso (anticuerpo anti-integrina a5b1; mol}ecula de ácido nucleico que lo codifica; vector y célula huesped; método de producción; composición farmacéutica que lo comprende; su uso para inhibir la angiogénesis y/o permeabilidad vascular y cáncer entre otras patologías; y método de detección de la integrina a5b1).
WO2009094634A1 (en) * 2008-01-24 2009-07-30 Esperance Pharmaceuticals Lytic domain fusion constructs and methods of making and using same
TWI504409B (zh) 2009-03-25 2015-10-21 Genentech Inc 新穎抗－α５β１抗體及其用途
US20110319335A1 (en) 2010-06-23 2011-12-29 Xiaodong Feng Combined administration of integrin receptor antagonists for anti-angiogenic therapy
AU2012230809B2 (en) * 2011-03-23 2017-06-29 The Regents Of The University Of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
US8946159B2 (en) * 2011-12-22 2015-02-03 California Northstate College Of Pharmacy, Llc Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment
WO2017069627A1 (en) 2015-10-23 2017-04-27 Universiteit Twente Integrin binding peptides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
WO1997033887A1 (en) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
JP6434021B2 (ja) 2013-08-07 2018-12-05 アビニシオ テクノロジー エルエルシー データフィードの管理

Also Published As

Publication number Publication date
EP2044955A3 (en) 2009-04-29
EP2044955A2 (en) 2009-04-08
CY1109062T1 (el) 2014-07-02
ES2322723T3 (es) 2009-06-25
WO1999058139A3 (en) 2000-02-10
EP2327451A3 (en) 2012-05-09
JP2009051815A (ja) 2009-03-12
DK1075277T4 (da) 2012-12-17
AU3973499A (en) 1999-11-29
ES2322723T5 (es) 2013-03-11
EP2327451B1 (en) 2013-10-23
DK1075277T3 (da) 2009-05-04
JP2002514605A (ja) 2002-05-21
AU746662B2 (en) 2002-05-02
EP1075277B1 (en) 2009-02-25
EP1075277A2 (en) 2001-02-14
CA2328414A1 (en) 1999-11-18
CA2328414C (en) 2014-04-15
EP1075277B2 (en) 2012-10-31
ATE423570T1 (de) 2009-03-15
WO1999058139A2 (en) 1999-11-18
EP2327451A2 (en) 2011-06-01
JP4312822B2 (ja) 2009-08-12
DE69940465D1 (de) 2009-04-09

Similar Documents

Publication Publication Date Title
PT1075277E (pt) Métodos para detectar e inibir a angiogénese
CA2421007A1 (en) Method for detection of htr and htert telomerase-associated rna in plasma or serum
BR0016652A (pt) Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo
WO2003048333A3 (en) Endorepellin compositions and methods for inhibiting angiogenesis
HK1069767A1 (en) Methods for inhibiting ocular processes
ZA995161B (en) Visual blood glucose test strip.
WO1999063115A3 (en) Use of cathepsin s in the diagnosis and treatment of endometriosis
WO1993000064A3 (en) Evaluation and treatment of the multidrug resistance phenotype
GB0203446D0 (en) Detection and/or monitoring of synuclein-related diseases
WO2005054503A3 (en) Biomarkers for graft rejection
WO1995024650A3 (en) Methods of diagnosing and treating preeclampsia
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
WO2006040481A3 (fr) Procede de diagnostic et traitement de la maladie de crohn
WO2006027192A3 (en) Biomarkers for acute graft rejection
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2001087239A3 (en) Methods of affecting laminin 5 processing
AU2003258648A1 (en) Diagnosis of chronic rejection
HK1014207A1 (en) Method for quantifying extracellular bpi in body fluids
WO2002004952A3 (en) Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
AU2002367317A1 (en) Psoriasin expression by breast epithelial cells
WO2001098471A8 (en) Human phosphodiesterases
WO2002012887A3 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
WO1999047150A3 (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
WO2001010384A3 (en) Method for identifying compounds for treatment of insulin resistance
WO1999035169A3 (en) Methods and compositions for treating and diagnosing insulin related disorders